Continued treatment with OMS721 for blood clotting disorders
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial provides continued access to the study drug OMS721 for people who have already completed a previous OMS721 trial and whose doctor thinks more treatment could help. It is for patients with certain blood clotting disorders, such as atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), or complications after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of thrombotic microangiopathy (a blood clotting condition) related to aHUS, TTP, or a stem cell transplant.
- You must have already completed treatment in the earlier OMS721 trial (OMS721-TMA-001).
- Your doctor must believe that continuing OMS721 treatment could be helpful for you.
- You must not have a known allergy to OMS721 or any of its ingredients.
- You must not have any other serious medical condition that would make OMS721 treatment risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This trial tests a new medicine for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS) that is still active despite other treatments. The drug aims to stop the ongoing damage to blood cells and kidneys.
This trial tests a new medicine called KP104 for people who have lupus and a related condition where small blood clots form and can damage organs like the kidneys. The goal is to see if the drug is safe and whether it helps improve blood counts and kidney function.
This study continues to give the drug NTQ5082 to people who already took part in an earlier trial and saw benefits. It aims to see how well the drug works over a longer period and how safe it is.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Hear when a new Thrombotic Microangiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.